SPHK1 and triple-negative breast carcinoma: A combination of the non-specific SphK1 inhibitor SKI-II with gefitinib significantly inhibited growth of xenograft MDA-MB-468 triple-negative breast cancer (TNBC) tumours, whereas neither SKI-II nor gefitinib alone had any effects.73